{"id":871102,"date":"2025-08-05T16:39:43","date_gmt":"2025-08-05T20:39:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-raises-2025-financial-guidance-ranges-and-reports-strong-second-quarter-2025-results\/"},"modified":"2025-08-05T16:39:43","modified_gmt":"2025-08-05T20:39:43","slug":"halozyme-raises-2025-financial-guidance-ranges-and-reports-strong-second-quarter-2025-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-raises-2025-financial-guidance-ranges-and-reports-strong-second-quarter-2025-results\/","title":{"rendered":"HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Total Revenue Increased 41% YOY to $326 million<\/span> and Royalty Revenue Increased 65% YOY to $206 million<\/span><\/i>\n <\/p>\n

\n Net Income Increased 77% YOY to $165 million<\/span>; Adjusted EBITDA Increased 65% YOY to $226 million<\/span>; GAAP Diluted EPS Increased 85% YOY to $1.33<\/span>; Non-GAAP Diluted EPS Increased 69% YOY to $1.54<\/span>1<\/sup><\/i>\n <\/p>\n

\n Raising 2025 Financial Guidance Ranges for Total Revenue to $1,275<\/span> – $1,355 million<\/span>, Representing YOY Growth of 26% – 33%, Adjusted EBITDA to $865<\/span> – $915 million<\/span>, Representing YOY Growth of 37% – 45% and Non-GAAP Diluted EPS to $6.00<\/span> – $6.40<\/span>, Representing YOY Growth of 42% – 51%1<\/sup><\/i>\n <\/p>\n

\n Announcing Third $250 million<\/span> Share Repurchase Tranche Under $750 million<\/span> Authorized Plan\u00a0 <\/i>\n <\/p>\n

\n
\n SAN DIEGO<\/span>
\n <\/span>, Aug. 5, 2025<\/span><\/span> \/PRNewswire\/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the second quarter ended June\u00a030, 2025, provided an update on its recent corporate activities and raised its 2025 financial guidance.<\/p>\n

“We are very excited to report another quarter of exceptional growth with a 65% increase in royalty revenue driven by our current three blockbuster therapies, DARZALEX SC, Phesgo, and VYVGART Hytrulo. In the second quarter, four notable approvals include RYBREVANT SC in Europe<\/span>, VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in Europe<\/span> and the VYVGART Hytrulo pre-filled syringe for gMG and CIDP in the U.S and Europe<\/span>. Additional regulatory milestones were achieved with ENHANZE, including new indications and geographic expansion for DARZALEX SC, \u00a0Opdivo SC, HYQVIA and Phesgo, which will further accelerate our future growth trajectory and enhance patient access. Based on the strong performance and growth trends, we are pleased to increase our full-year 2025 financial guidance ranges for the second time this year,” said Dr. Helen Torley<\/span>, President and CEO, Halozyme.<\/p>\n

“The strong results highlight the momentum and durability across our business, powered by high-margin royalty streams and increasing global demand for our industry-leading ENHANZE drug delivery technology. In the quarter, we completed a total of $303 million<\/span> in share repurchases, including the $250 million<\/span> program that we announced in May. Our outperformance and strong cash generation supports a balanced capital allocation strategy, including investing in growth through M&A and returning capital to shareholders,” concluded Dr. Torley.<\/p>\n

\n Second Quarter and Recent Corporate Highlights:<\/b>\n <\/p>\n